Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis

The European Medicines Agency has approved a multicomponent serogroup B meningococcal vaccine (Bexsero®) for use in individuals of 2 months of age and older. A cost-effectiveness analysis (CEA) from the societal and Italian National Health Service perspectives was performed in order to evaluate the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hum Vaccin Immunother
Autors principals: Gasparini, Roberto, Landa, Paolo, Amicizia, Daniela, Icardi, Giancarlo, Ricciardi, Walter, de Waure, Chiara, Tanfani, Elena, Bonanni, Paolo, Lucioni, Carlo, Testi, Angela, Panatto, Donatella
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2016
Matèries:
Research Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994748/
https://ncbi.nlm.nih.gov/pubmed/27163398
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2016.1160177
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars